Insider trade

CEO sold ~$17K of OVID shares in the open market

Traded Feb 23, 2026 · Filed Mar 2, 2026

Why it stands out

The CEO of Ovid Therapeutics sold $17K of Ovid Therapeutics shares. The filing references tax withholding.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO<$25KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$16,901

Shares × reported transaction price

Timing vs results

103 days after results of Nov 12, 2025, 23 days before results of Mar 18, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references tax withholding

Only flagged when a footnote says so; never inferred

Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.